Ana Carmona Alonso

Coordinadora Ensayos Clínicos Fase I at Vall d'Hebron Institute of Oncology (VHIO)

Ana Carmona Alonso is a clinical trial coordinator specializing in phase I oncology trials at Vall d'Hebron Institute of Oncology (VHIO) since April 2022. Previously, Ana worked as a data manager for oncology clinical trials at IMIBIC from November 2021 to April 2022 and participated in an Erasmus+ program at the University of Portsmouth in 2017, focusing on cancer research. Ana holds a Bachelor's degree in Pharmacy from Universidad de Granada, with additional studies at Universidad Complutense de Madrid and Università degli Studi di Milano. Furthermore, Ana completed a Master's program in Study Coordination at ESAME Pharmaceutical Business School in 2021.

Links

Previous companies


Org chart

No direct reports

Teams


Offices

This person is not in any offices


Vall d'Hebron Institute of Oncology (VHIO)

Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO) has established itself as a cancer research center of proven excellence internationally. It is thanks to Josep's directorship and VHIO's optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease. Located within the Vall d´Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d´Hebron University Hospital physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients. VHIO's pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread and more effectively treating even the most undruggable tumour types. VHIO's translation toward precision oncology.


Industries

Headquarters

Spain

Employees

201-500

Links